Safety and efficacy of nadifloxacin versus clindamycin observed in a tertiary care teaching hospital of Deccan Plateau

S Kumar, Tamilisetti Vidya Sagar
{"title":"Safety and efficacy of nadifloxacin versus clindamycin observed in a tertiary care teaching hospital of Deccan Plateau","authors":"S Kumar, Tamilisetti Vidya Sagar","doi":"10.18231/j.ijpp.2023.007","DOIUrl":null,"url":null,"abstract":"Acne vulgaris is characterised by excess sebum production and inflammatory reaction in sebaceous glands. As propionibacterium is involved in aggravation of acne, antimicrobials like nadifloxacin and clindamycin were found to be effective in treatment.Comparison of nadifloxacin with clindamycin in terms of inflammatory and non-inflammatory lesion count and global improvement rating, when given in combination with benzoyl peroxide in patients in acne vulgarisNadifloxacin 1%, benzoyl peroxide 2.5% and clindamycin 1% were used as topical treatment option. Study cohort was randomly divided into two groups: Nadifloxacin group and Clindamycin group. All subjects who were included in the study were instructed to apply a thin layer of medication over acne lesions; benzoyl peroxide 2.5% gel once daily at bedtime and clindamycin 1% gel or Nadifloxacin 1% gel twice daily. Efficacy is analysed by comparing changes in total, inflammatory and non-inflammatory lesion counts, In addition, global improvement was rated by patients using a six-point scale (worsening, no improvement, slight improvement, moderate improvement, good improvement, clearance) at end of treatment.There is progressive decline in number of inflammatory and non-inflammatory lesions in both groups. Analysis of lesion counts not showed any significant difference in between two groups. In global improvement rating scale, more number of patients using nadifloxacin with benzoyl peroxide reported good improvement compared to patients using Clindamycin with benzoyl peroxide. No patient in any group reported worsening of lesions. None of patients in study groups reported clearance. Two adverse events were reported during study, they were, burning sensation and dryness. There was no significant difference in incidence of adverse events in both treatment groups.Topical Nadifloxacin, a new fluoroquinolone is effective, tolerable and safe for mild or moderate facial acne. Its clinical effectiveness is equivalent to clindamycin when used as add-on therapy to benzoyl peroxide.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmacy and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijpp.2023.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acne vulgaris is characterised by excess sebum production and inflammatory reaction in sebaceous glands. As propionibacterium is involved in aggravation of acne, antimicrobials like nadifloxacin and clindamycin were found to be effective in treatment.Comparison of nadifloxacin with clindamycin in terms of inflammatory and non-inflammatory lesion count and global improvement rating, when given in combination with benzoyl peroxide in patients in acne vulgarisNadifloxacin 1%, benzoyl peroxide 2.5% and clindamycin 1% were used as topical treatment option. Study cohort was randomly divided into two groups: Nadifloxacin group and Clindamycin group. All subjects who were included in the study were instructed to apply a thin layer of medication over acne lesions; benzoyl peroxide 2.5% gel once daily at bedtime and clindamycin 1% gel or Nadifloxacin 1% gel twice daily. Efficacy is analysed by comparing changes in total, inflammatory and non-inflammatory lesion counts, In addition, global improvement was rated by patients using a six-point scale (worsening, no improvement, slight improvement, moderate improvement, good improvement, clearance) at end of treatment.There is progressive decline in number of inflammatory and non-inflammatory lesions in both groups. Analysis of lesion counts not showed any significant difference in between two groups. In global improvement rating scale, more number of patients using nadifloxacin with benzoyl peroxide reported good improvement compared to patients using Clindamycin with benzoyl peroxide. No patient in any group reported worsening of lesions. None of patients in study groups reported clearance. Two adverse events were reported during study, they were, burning sensation and dryness. There was no significant difference in incidence of adverse events in both treatment groups.Topical Nadifloxacin, a new fluoroquinolone is effective, tolerable and safe for mild or moderate facial acne. Its clinical effectiveness is equivalent to clindamycin when used as add-on therapy to benzoyl peroxide.
在德干高原某三级保健教学医院观察纳氟沙星与克林霉素的安全性和有效性
寻常痤疮的特征是皮脂分泌过多和皮脂腺的炎症反应。由于丙酸杆菌与痤疮的恶化有关,抗微生物药物如纳地沙星和克林霉素被发现是有效的治疗方法。比较纳地沙星与克林霉素联合过氧化苯甲酰治疗寻常痤疮患者的炎性和非炎性病变计数及整体改善评分,以纳地沙星1%、过氧化苯甲酰2.5%和克林霉素1%作为局部治疗选择。研究队列随机分为两组:纳地沙星组和克林霉素组。所有参与研究的受试者都被要求在痤疮损伤处涂抹一层薄薄的药物;过氧化苯甲酰2.5%凝胶每日1次,克林霉素1%凝胶或纳地沙星1%凝胶每日2次。通过比较总、炎症和非炎症病变计数的变化来分析疗效。此外,在治疗结束时,患者使用6分制(恶化、无改善、轻微改善、中度改善、良好改善、清除)对整体改善进行评分。两组的炎性和非炎性病变数量均逐渐减少。病变计数分析显示两组间无显著差异。在全球改善评定量表中,与克林霉素联合过氧化苯甲酰相比,使用纳地沙星联合过氧化苯甲酰的患者报告良好改善的人数更多。没有任何一组患者报告病变恶化。研究组中没有患者报告清除。在研究过程中报告了两个不良事件,它们是烧灼感和干燥。两组患者不良事件发生率无显著差异。纳地氟沙星是一种新型氟喹诺酮类药物,对轻度或中度面部痤疮有效、耐受、安全。作为过氧化苯甲酰的附加治疗,其临床疗效与克林霉素相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信